Roivant Sciences (ROIV) Intangibles (2022 - 2024)
Roivant Sciences' (ROIV) quarterly Intangibles came in at $136.0 million in Q2 2024, down 6.22% YoY from $145.0 million in Q3 2023, and down 1.33% on a QoQ basis from $137.8 million in Q1 2024.
Roivant Sciences (ROIV) Intangibles (2022 - 2024) Analysis & Trends
Roivant Sciences (ROIV) has 3 years of Intangibles data on file, last reported at $136.0 million in Q2 2024.
- Quarterly Intangibles fell 6.22% year-over-year to $136.0 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $136.0 million (down 6.22% YoY) and the FY2024 annual result came in at $137.8 million, down 9.69% from the prior year.
- Intangibles fell to $136.0 million in Q2 2024, from $137.8 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $166.5 million in Q4 2023 to a low of $136.0 million in Q2 2024.
- A 3-year average of $145.9 million and a median of $145.0 million in 2023 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2023 — Intangibles advanced 13.94% — and 2024, when it fell 9.69%.
- Tracing ROIV's Intangibles over 3 years: stood at $146.1 million in 2022, then advanced by 13.94% to $166.5 million in 2023, then retreated by 18.3% to $136.0 million in 2024.
- The last three Intangibles figures came in at $136.0 million (Q2 2024), $137.8 million (Q1 2024), and $166.5 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 136.01 Mn |
| Mar 31, 2024 | 137.84 Mn |
| Dec 31, 2023 | 166.47 Mn |
| Sep 30, 2023 | 140.62 Mn |
| Jun 30, 2023 | 145.04 Mn |
| Mar 31, 2023 | 152.63 Mn |
| Dec 31, 2022 | 146.11 Mn |
| Sep 30, 2022 | 143.21 Mn |
| Jun 30, 2022 | 145.43 Mn |